Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Pseudomyxoma Peritonei 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, B-Cell 1Endometrial Neoplasms 1Appendiceal Neoplasms 1

Interventions

Rituximab 78Cyclophosphamide 76fludarabine phosphate 45Peripheral Blood Stem Cell Transplantation 41Mycophenolic Acid 39Tacrolimus 35Whole-Body Irradiation 33Radiotherapy 29Busulfan 29Cyclosporine 27Antilymphocyte Serum 27Etoposide 25Filgrastim 24Methotrexate 22Melphalan 22Lenalidomide 15Cytarabine 15Cord Blood Stem Cell Transplantation 14fludarabine 13Methylprednisolone 13Bortezomib 13orelabrutinib 12Dexamethasone 12sargramostim 11obinutuzumab 11Sirolimus 9Carmustine 9venetoclax 8Vincristine 8Prednisone 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, B-Cell, Marginal Zone × Lansoprazole × Clear all
NCT02388581 2016-03-25

First-line Antibiotic Therapy for Early-stage HP(+) Gastric Pure DLBCL

National Health Research Institutes, Taiwan

Phase 2 Unknown
30 enrolled
Lymphoid

Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡